Gene-Edited immune cells take on aggressive brain tumors
NCT ID NCT06815029
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This phase 1 trial tests a new type of immunotherapy for people with recurrent or progressive high-grade gliomas, including glioblastoma. The treatment uses the patient's own T cells, which are genetically modified in the lab to target a protein called IL13Rα2 found on tumor cells, and also edited with CRISPR to resist signals that normally suppress immune attack. The cells are infused directly into the skull. The main goal is to evaluate safety and find the best dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TGFβR2KO/IL13Rα2 CAR T cells
What this could lead to
If successful, this approach could offer a new treatment option for patients with recurrent high-grade gliomas, a type of aggressive brain cancer with few effective therapies.
What could go wrong
This is an early phase 1 trial with only 27 participants, so safety and dosing are still being evaluated. The treatment involves intracranial infusion and carries risks such as cytokine release syndrome and neurotoxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact